Cliff Asness’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Cliff Asness’s Portfolio BLCM Stock Details BLCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-1,666	Closed	-$192K	–	2289
2017 Q3	$192K	Buy	+1,666	New	+$175K	﹤0.01%	2173

Other funds holding BLCM

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Cliff Asness's BLCM Position: Q4 2017 in Review

Cliff Asness sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q4 2017, closing a stake of 1,666 shares — an estimated $192K sold.

Cliff Asness first reported a position in BLCM in Q3 2017 and held it in 1 quarter. The position peaked at $192K in Q3 2017. 91 funds tracked by Wall St. Rank hold BLCM as of Q4 2017.

Cliff Asness reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
Cliff Asness sold 1,666 Bellicum Pharmaceuticals, Inc. shares in Q4 2017, an estimated $192K.
Cliff Asness first reported a position in Bellicum Pharmaceuticals, Inc. in Q3 2017 and held it in 1 quarter.
Cliff Asness's Bellicum Pharmaceuticals, Inc. position peaked at $192K in Q3 2017.
91 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q4 2017.

Based on AQR Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.